Table 2.
Cognitive performance by NC-AE medication use in The Women’s Interagency HIV Study.
| Total NC-AE medications
|
Generalized linear model†
|
|||||||
|---|---|---|---|---|---|---|---|---|
| Outcome | Obs | 0 | 1 | >1 | Overall | 1 vs. 0 | >1 vs. 0 | >1 vs. 1 |
| (n=1009) | (n=301) | (n=248) | ||||||
| M (SE) | M (SE) | M (SE) | p-value | p-value | p-value | p-value | ||
| Global NP | 1556 | 3.2 (0.10) | 3.4 (0.13) | 3.5 (0.14) | 0.08 | 0.07 | 0.07 | 0.86 |
| Memory | 1553 | 2.4 (0.09) | 2.4 (0.11) | 2.6 (0.12) | 0.23 | 0.86 | 0.09 | 0.18 |
| Learning | 1553 | 2.5 (0.08) | 2.6 (0.11) | 2.6 (0.12) | 0.16 | 0.11 | 0.13 | 0.95 |
| Attention/WM | 1398 | 2.3 (0.09) | 2.4 (0.11) | 2.2 (0.11) | 0.24 | 0.58 | 0.16 | 0.10 |
| Executive Function | 1540 | 2.8 (0.10) | 2.9 (0.13) | 3.0 (0.13) | 0.07 | 0.04 | 0.11 | 0.59 |
| Speed | 1555 | 2.6 (0.09) | 2.7 (0.11) | 2.8 (0.13) | 0.58 | 0.46 | 0.36 | 0.82 |
| Fluency | 1550 | 2.6 (0.09) | 2.6 (0.11) | 2.6 (0.12) | 0.90 | 0.85 | 0.97 | 0.75 |
| Motor | 1531 | 2.4 (0.09) | 2.6 (0.12) | 2.6 (0.13) | 0.19 | 0.13 | 0.16 | 0.98 |
Note. Bold=significant at p<0.05. WM=working memory; NP=neuropsychological. M = estimated mean T-score; SE = standard error; OR=odds ratio. NC-AE=non-ARV medication with known general adverse cognitive effects.
†
controlling for HIV− and HCV status, site, current employment status, depressive symptoms, heavy drinking, smoking, marijuana, crack, cocaine and/or heroin use.
*
after controlling the false discovery rate using the Benjamini-Hochberg procedure the overall association remained significant.